Lonza Partners with Cryoport and Strengthens its Vein-to-vein Delivery Network in Cell & Gene Therapy

Lonza and Cryoport, Inc announced their partnership in the cell and gene therapy field and across Lonza’s ‘vein-to-vein’ delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza’s customers and their patients.

Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics — including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines — as they prepare for the commercial launch of their respective therapies.

Lonza’s network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport’s logistics and bioservices solutions with Lonza’s manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.

Cryoport’s logistics system aims to provide Lonza’s clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport’s proprietary Cryoport Express® Shippers, this partnership incorporates Cryoport’s Cryoportal® Logistics Management Platform and SmartPak II™ Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport’s unique Chain of Compliance for regulatory solutions.

About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com

About Cryoport
Cryoport, Inc is the world’s premier provider of temperature-controlled supply chain solutions for the life sciences industry, serving the Biopharma, Human Reproductive, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information technology; smart, sustainable cold chain logistics; and biostorage/biobanking services, Cryoport helps its customers advance life sciences research, support life-saving advanced therapies and deliver vaccines, protein producing materials, and IVF treatments in over 100 countries around the world. For more information, visit www.cryoport.com